The FDA has granted the PARP inhibitor Rubraca (rucaparib) a breakthrough therapy designation for single-agent use in adult patients with BRCA1/2-positive metastatic castration-resistant prostate cancer (mCRPC) following at least one androgen receptor–directed therapy and taxane-based chemotherapy.
When given neoadjuvant chemotherapy before getting a radical cystectomy, patients with the basal subtype of muscle-invasive bladder cancer (MIBC) saw significantly improved overall survival (OS) compared to those who had a cystectomy alone, according to a recent study.